Composition: Levofloxacin Hemihydrate equivalent to Levofloxacin 250 mg, 500 mg or 750 mg per film-coated tablet.
Usage: Selected bacterial infections
Category: Antibiotic Drugs
Therapeutic category: Fluoroquinolone Antibiotic
SKU: Levofloxacin Tablets
Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations
Levofloxacin Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Levofloxacin Tablets 250 mg / 500 mg / 750 mg
Levofloxacin is a prescription fluoroquinolone antibacterial medicine used for selected infections caused by susceptible bacteria. The supplied film-coated tablets contain levofloxacin hemihydrate equivalent to 250 mg, 500 mg or 750 mg levofloxacin. Because fluoroquinolones can cause serious and potentially persistent adverse reactions, use should be guided by culture results, local resistance patterns, approved labeling and clinical assessment.
Manufacturer (as supplied): Healthy Life Pharma Pvt. Ltd. Exporter (as supplied): Healthy Inc. WHO-GMP status and export authorizations should be independently verified for the applicable manufacturing site and market.
| Product | Levofloxacin Tablets |
|---|---|
| Active ingredient | Levofloxacin Hemihydrate equivalent to Levofloxacin |
| Supplied strengths | 250 mg / 500 mg / 750 mg |
| Dosage form | Film-coated oral tablet |
| Therapeutic class | Fluoroquinolone antibiotic |
| Usage | Selected susceptible bacterial infections |
| SKU | Levofloxacin Tablets |
| Pharmacopoeia | IP specified for 250 mg and 500 mg variants; confirm product-specific standards for 750 mg |
| Packaging / shelf life | Confirm against approved artwork and stability data |
Key formulation considerations include API identity and potency, blend uniformity, tablet compression, appropriate film-coating performance, dissolution and stability. Product-specific claims about chiral purity, exact excipients, processing methods, coating composition and validated stability require supporting manufacturing records and should not be assumed.
Finished-product testing should follow the applicable registered specification and pharmacopoeial monograph, including identity, assay, uniformity, dissolution, impurities, packaging integrity and stability as relevant. Specific release limits or bioequivalence claims must be supported by approved specifications and studies.
Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. Depending on local authorization and bacterial susceptibility, it may be prescribed for selected community-acquired pneumonia, complicated urinary tract infection, pyelonephritis, chronic bacterial prostatitis and other approved bacterial infections.
Stewardship: For acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and uncomplicated urinary tract infection, fluoroquinolones are generally reserved for patients with no suitable alternative in markets carrying these restrictions. It does not treat viral colds or flu.
For B2B enquiries, request product-specific dossiers, current GMP evidence, certificates of analysis, certificates of pharmaceutical product, stability data and destination-market registration status as applicable. Availability of CTD/ACTD documents, specific certificates and shipping terms should be confirmed with the supplier rather than presumed.
Q: What strengths are listed?
A: 250 mg, 500 mg and 750 mg film-coated tablets.
Q: Can it treat every chest infection?
A: No. It is only appropriate for certain bacterial infections when the organism is susceptible and the benefits outweigh risks.
Q: What should be separated from the dose?
A: Magnesium/aluminum antacids, iron, zinc-containing multivitamins and sucralfate can reduce absorption; consult the product label for spacing, commonly at least two hours. Ordinary dairy food is not the same as taking these supplements.
Q: Is tendon injury possible?
A: Yes. Tendinitis or tendon rupture may occur, including after treatment ends. Stop the medicine and obtain medical advice promptly if tendon pain or swelling develops.
Strength, frequency and treatment duration depend on the infection, bacterial susceptibility, kidney function and local prescribing information. Renal dose adjustment is generally needed with reduced creatinine clearance (commonly below 50 mL/min for many regimens). Use only as prescribed; do not select a 5-day or other course based solely on tablet strength. Oral tablets may generally be taken with or without food; follow the approved label for interactions with mineral-containing products.
Serious warnings: Tendinitis and tendon rupture; potentially irreversible peripheral neuropathy; central nervous system or psychiatric effects; exacerbation of myasthenia gravis; dysglycemia; QT prolongation; severe allergic reactions; and Clostridioides difficile-associated diarrhea. Additional caution may apply for patients at risk of aortic aneurysm or dissection. Seek urgent medical care for severe allergic symptoms, new nerve symptoms, serious confusion, severe hypoglycemia, or sudden severe chest, back or abdominal pain. Common adverse effects include nausea, diarrhea, headache and dizziness.
Discuss pregnancy, breastfeeding, age-related risks, corticosteroid use, kidney disease and concomitant medicines with the prescriber.
Store according to the approved product label, in the original protective packaging and away from excess moisture, heat and light. Confirm the exact storage temperature and shelf life on the marketed pack. Keep out of reach of children.